ClearNote Health Secures $52 Million in Series D Financing and Strengthens Leadership Team to Accelerate Growth in Early Cancer Detection

Proceeds will support continued commercial expansion, operational scale-up, clinical study execution, and product development * Clinical oncology ...
Ventureburn

ClearNote Health Secures $52 Million to Scale Early Cancer Detection

ClearNote Health secures $52 million to scale early cancer detection and expand global clinical and commercial operations.
The Manila Times

FDA Breakthrough Device Designation Marks Major Milestone for Gene Solutions' SPOT-MAS 10 Multi-Cancer Screening Test

FDA Breakthrough Device Designation Marks Major Milestone for Gene Solutions' SPOT-MAS 10 Multi-Cancer Screening Test ...
Labroots

Pancreatic Cancer Diagnosis Could Be Accelerated with AI

Pancreatic cancer remains one of the deadliest malignancies, due in large part to challenges with early diagnosis.  Advanced pancreatic cancer diagnos | Cancer ...
European Medical Journal

MALDI Imaging Advances Rare Ampullary Cancer Diagnosis

Matrix assisted laser desorption ionisation imaging combined with machine learning may improve rare ampullary cancer ...
Vietnam Investment Review on MSN

FDA grants breakthrough device designation to Gene Solutions SPOT MAS 10 multi cancer screening test

SINGAPORE, May 28, 2026 /PRNewswire/ -- Gene Solutions, a global biotechnology company advancing accessible genomic solutions for cancer detection and precision oncology, today announced that the U.S.